Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Long-term depression (mmu04730)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
AK082687
KLA  ATP  ATP+KLA
AK082687 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230086D05 product:unclassifiable, full insert sequence [AK082687] KLA 1.00 .95 1.04 .95 1.01 1.01 1.14
ATP 1.00 .96 1.03 1.05 .92 1.02 .89
KLA/ATP 1.01 1.09 1.04 1.03 1.05 1.01 1.02
Araf
KLA  ATP  ATP+KLA
NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
BE980448
KLA  ATP  ATP+KLA
BE980448 gb|UI-M-BG2-bci-g-09-0-UI.s1 NIH_BMAP_MSC_S1 Mus musculus cDNA clone UI-M-BG2-bci-g-09-0-UI 3. [BE980448] KLA .97 .93 .89 .98 .96 .95 .93
ATP 1.02 1.03 .99 .97 .99 .97 1.01
KLA/ATP .91 .88 .84 .89 .93 .96 .91
Braf
KLA  ATP  ATP+KLA
NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Cacna1a
KLA  ATP  ATP+KLA
NM_007578 calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (Cacna1a), mRNA [NM_007578] KLA .71 .66 .61 .63 .60 .71 .72
ATP 1.07 1.04 .89 1.08 .71 .56 .75
KLA/ATP .71 .72 .85 .69 .64 .63 .68
Crhr1
KLA  ATP  ATP+KLA
NM_007762 corticotropin releasing hormone receptor 1 (Crhr1), mRNA [NM_007762] KLA 1.00 1.05 1.06 1.05 1.06 1.06 1.05
ATP 1.04 .97 1.03 1.06 1.09 1.07 1.03
KLA/ATP 1.08 1.10 1.05 1.11 1.10 1.05 1.13
Gna11
KLA  ATP  ATP+KLA
NM_010301 guanine nucleotide binding protein, alpha 11 (Gna11), mRNA [NM_010301] KLA .62 .65 .69 .79 .94 1.00 .96
ATP 1.00 .94 .63 .53 .79 1.13 1.22
KLA/ATP .64 .60 .56 .55 .81 1.16 1.18
Gna12
KLA  ATP  ATP+KLA
M63659 gb|Mouse G-alpha-12 protein mRNA, complete cds [M63659] KLA .48 .48 .49 .40 .44 .59 .60
ATP 1.08 1.15 1.00 1.39 1.02 .65 .73
KLA/ATP .52 .50 .51 .52 .56 .66 .52
Gna13
KLA  ATP  ATP+KLA
NM_010303 guanine nucleotide binding protein, alpha 13 (Gna13), mRNA [NM_010303] KLA 1.96 2.10 2.12 1.85 2.36 2.02 1.54
ATP 1.04 1.13 1.19 3.56 6.50 2.32 1.44
KLA/ATP 2.17 2.07 1.67 3.72 6.89 3.91 2.27
Gnai1
KLA  ATP  ATP+KLA
NM_010305 guanine nucleotide binding protein (G protein), alpha inhibiting 1 (Gnai1), mRNA [NM_010305] KLA .95 1.01 1.01 1.00 1.09 1.10 1.08
ATP 1.06 1.06 .99 1.15 1.02 .94 .99
KLA/ATP 1.02 1.04 .99 1.16 1.01 1.02 1.13
Gnai2
KLA  ATP  ATP+KLA
NM_008138 guanine nucleotide binding protein (G protein), alpha inhibiting 2 (Gnai2), mRNA [NM_008138] KLA .74 .79 .82 .74 .91 .97 1.10
ATP 1.07 1.16 .78 1.12 .78 .48 .82
KLA/ATP .91 .81 .53 .80 .60 .68 .87
Gnai3
KLA  ATP  ATP+KLA
NM_010306 guanine nucleotide binding protein (G protein), alpha inhibiting 3 (Gnai3), mRNA [NM_010306] KLA 1.23 1.24 1.14 1.06 .99 1.15 1.09
ATP .96 .93 .86 .64 1.34 2.02 1.35
KLA/ATP 1.20 1.24 .97 .76 1.21 1.62 1.17
Gnao1
KLA  ATP  ATP+KLA
NM_001113384 guanine nucleotide binding protein, alpha O (Gnao1), transcript variant B, mRNA [NM_001113384] KLA .95 .98 1.03 1.00 1.02 1.02 .99
ATP .95 1.02 1.01 1.08 .99 .97 .95
KLA/ATP 1.05 1.04 1.10 .99 1.01 .98 1.03
Gnao1
KLA  ATP  ATP+KLA
NM_010308 guanine nucleotide binding protein, alpha O (Gnao1), transcript variant A, mRNA [NM_010308] KLA .98 .96 1.00 .97 .96 .97 1.01
ATP 1.12 .99 1.05 .87 .97 1.02 1.01
KLA/ATP .93 1.00 .99 1.01 1.05 1.07 .98
Gnaq
KLA  ATP  ATP+KLA
NM_008139 guanine nucleotide binding protein, alpha q polypeptide (Gnaq), mRNA [NM_008139] KLA .82 .82 .69 .64 .60 .55 .55
ATP 1.06 1.02 .87 .67 .50 .66 .57
KLA/ATP .82 .79 .66 .55 .41 .33 .48
Gnas
KLA  ATP  ATP+KLA
AF107847 neuroendocrine-specific Golgi protein p55 isoform 1 (XLalphas) alternatively spliced mRNA, complete cds. [AF107847] KLA 1.04 .94 1.00 1.05 1.04 .98 1.00
ATP .98 .97 .96 1.00 .99 .98 1.02
KLA/ATP 1.04 1.02 .96 .95 1.01 .96 1.01
Gnas
KLA  ATP  ATP+KLA
AK017423 10 days neonate head cDNA, RIKEN full-length enriched library, clone:5530400H20 product:novel noncoding RNA overlapping the exon 1A, 1 and 2 of Gnas, full insert sequence. [AK017423] KLA .85 1.08 .97 .92 1.05 1.03 1.08
ATP .99 1.30 2.11 1.73 1.23 1.01 1.02
KLA/ATP .96 1.06 1.58 1.34 1.29 1.05 .91
Gnas
KLA  ATP  ATP+KLA
NM_001077510 GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus (Gnas), transcript variant 8, mRNA [NM_001077510] KLA .99 1.03 .97 .91 1.03 .95 .97
ATP 1.04 1.19 1.15 1.61 1.24 .91 1.00
KLA/ATP 1.06 .97 1.01 1.46 1.04 .85 1.01
Gnas
KLA  ATP  ATP+KLA
S49980 gb|stimulatory G protein alpha subunit {clone WC-16} [mice, whole cochlea, mRNA Partial, 356 nt]. [S49980] KLA .91 .88 1.03 .87 .90 .84 1.01
ATP 1.16 1.22 1.02 1.55 1.16 .80 .99
KLA/ATP 1.01 1.13 .86 1.12 .97 .85 1.08
Gnaz
KLA  ATP  ATP+KLA
NM_010311 guanine nucleotide binding protein, alpha z subunit (Gnaz), mRNA [NM_010311] KLA 1.04 1.02 1.02 1.04 .95 .98 1.03
ATP 1.00 1.03 .98 1.03 1.08 1.03 .96
KLA/ATP 1.08 1.03 1.02 1.04 1.01 1.00 1.02
Gria1
KLA  ATP  ATP+KLA
NM_008165 glutamate receptor, ionotropic, AMPA1 (alpha 1) (Gria1), transcript variant 2, mRNA [NM_008165] KLA .97 1.02 1.02 1.01 1.03 1.02 1.11
ATP 1.03 .97 1.05 1.03 1.01 1.01 1.01
KLA/ATP 1.02 .99 1.01 1.06 1.15 1.06 1.05
Gria2
KLA  ATP  ATP+KLA
BC048248 glutamate receptor, ionotropic, AMPA2 (alpha 2), mRNA (cDNA clone MGC:54603 IMAGE:6494013), complete cds. [BC048248] KLA 1.00 1.01 1.05 1.00 1.03 .97 1.06
ATP .98 1.00 1.00 .96 1.03 1.05 1.04
KLA/ATP .98 1.08 .99 1.04 1.06 1.02 1.05
Gria2
KLA  ATP  ATP+KLA
NM_013540 glutamate receptor, ionotropic, AMPA2 (alpha 2) (Gria2), transcript variant 2, mRNA [NM_013540] KLA 1.02 1.02 .98 1.01 .98 1.02 1.01
ATP .95 1.01 .95 .99 1.09 1.02 1.09
KLA/ATP 1.06 .92 .96 .99 1.00 1.03 1.00
Gria3
KLA  ATP  ATP+KLA
AK161163 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4831401I16 product:glutamate receptor, ionotropic, AMPA3 (alpha 3), full insert sequence. [AK161163] KLA 1.01 .96 .97 .95 .99 .84 .81
ATP 1.05 1.04 1.07 .86 .88 .84 .65
KLA/ATP .94 .95 1.06 .83 .79 .75 .66
Gria3
KLA  ATP  ATP+KLA
NM_016886 glutamate receptor, ionotropic, AMPA3 (alpha 3) (Gria3), mRNA [NM_016886] KLA 1.04 .95 1.05 .98 .98 .97 .95
ATP 1.00 1.08 1.01 .97 .93 .98 .97
KLA/ATP 1.03 .93 .93 .98 .96 1.03 .89
Grid2
KLA  ATP  ATP+KLA
AK032669 10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:6530411F08 product:glutamate receptor, ionotropic, delta 2, full insert sequence. [AK032669] KLA 1.00 1.02 1.01 1.01 1.01 1.01 1.00
ATP 1.01 1.01 .99 .99 1.01 1.01 1.00
KLA/ATP 1.02 1.01 1.01 1.02 .99 1.01 .99
Grid2
KLA  ATP  ATP+KLA
AK036230 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630046P05 product:glutamate receptor, ionotropic, delta 2, full insert sequence. [AK036230] KLA 1.01 .97 1.01 .96 .96 .96 1.06
ATP 1.00 1.01 1.01 .97 1.00 .97 1.03
KLA/ATP 1.02 1.06 1.02 .92 .95 .95 .99
Grm1
KLA  ATP  ATP+KLA
NM_016976 glutamate receptor, metabotropic 1 (Grm1), transcript variant 1, mRNA [NM_016976] KLA 1.16 1.07 1.10 1.18 1.08 1.04 1.15
ATP 1.06 1.05 1.02 .99 1.00 1.09 1.02
KLA/ATP 1.04 1.12 1.06 1.11 1.10 1.32 1.35
Gsbs
KLA  ATP  ATP+KLA
AF071562 G-substrate mRNA, complete cds. [AF071562] KLA 1.01 .99 .99 1.00 1.05 .98 .98
ATP 1.02 1.03 1.04 1.00 .93 .93 .97
KLA/ATP 1.00 .97 .96 .88 1.00 .93 .97
Gsbs
KLA  ATP  ATP+KLA
NM_011153 G substrate (Gsbs), mRNA [NM_011153] KLA 1.02 1.09 .96 1.01 1.04 1.03 1.00
ATP 1.01 .99 1.02 1.08 .92 1.12 1.06
KLA/ATP 1.02 .91 1.05 1.01 1.04 1.01 1.06
Gucy1a3
KLA  ATP  ATP+KLA
NM_021896 guanylate cyclase 1, soluble, alpha 3 (Gucy1a3), mRNA [NM_021896] KLA 1.01 1.01 1.04 .99 .99 .97 .99
ATP .99 1.01 .99 .99 .97 1.02 1.02
KLA/ATP 1.00 .96 1.00 .99 .98 1.04 .99
Gucy1b2
KLA  ATP  ATP+KLA
NM_172810 guanylate cyclase 1, soluble, beta 2 (Gucy1b2), mRNA [NM_172810] KLA 1.02 1.03 1.03 1.09 .95 1.06 .91
ATP 1.01 1.03 1.01 1.08 .96 1.04 .90
KLA/ATP 1.04 1.03 .99 1.05 .97 .96 .84
Gucy1b3
KLA  ATP  ATP+KLA
NM_017469 guanylate cyclase 1, soluble, beta 3 (Gucy1b3), mRNA [NM_017469] KLA .99 .99 .99 1.01 .98 .98 1.00
ATP .98 .98 .98 .98 .98 1.00 1.01
KLA/ATP .96 .99 .98 1.01 .99 .99 .99
Hras1
KLA  ATP  ATP+KLA
NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Igf1
KLA  ATP  ATP+KLA
AK050118 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730016P09 product:unclassifiable, full insert sequence. [AK050118] KLA .13 .14 .15 .16 .22 .34 .48
ATP 1.78 2.05 1.37 .72 .34 .41 .58
KLA/ATP .24 .45 .50 .24 .20 .26 .68
Igf1
KLA  ATP  ATP+KLA
NM_010512 insulin-like growth factor 1 (Igf1), transcript variant 1, mRNA [NM_010512] KLA .84 .78 .76 .67 .54 .48 .59
ATP .97 .98 1.13 1.13 1.03 .88 .89
KLA/ATP .82 .81 .93 .86 .83 .65 .89
Igf1
KLA  ATP  ATP+KLA
NM_184052 insulin-like growth factor 1 (Igf1), transcript variant 2, mRNA [NM_184052] KLA .77 .82 .76 .65 .60 .52 .69
ATP 1.01 1.07 .98 1.06 1.03 .78 .94
KLA/ATP .89 .86 .77 .80 .75 .65 .89
Igf1r
KLA  ATP  ATP+KLA
NM_010513 insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513] KLA 1.32 1.32 1.08 .91 .55 .48 .45
ATP 1.03 1.06 1.06 1.29 1.31 1.45 .47
KLA/ATP 1.30 1.37 1.11 1.00 .93 1.02 .45
Itpr1
KLA  ATP  ATP+KLA
NM_010585 inositol 1,4,5-triphosphate receptor 1 (Itpr1), mRNA [NM_010585] KLA 3.66 3.69 6.74 8.11 7.08 4.40 1.22
ATP 1.08 .95 1.19 .94 1.09 1.00 .68
KLA/ATP 3.48 3.58 5.86 6.03 4.01 2.31 .97
Itpr2
KLA  ATP  ATP+KLA
NM_019923 inositol 1,4,5-triphosphate receptor 2 (Itpr2), transcript variant 1, mRNA [NM_019923] KLA 1.41 1.38 1.43 1.42 1.30 1.07 1.01
ATP 1.00 1.00 .97 .97 1.07 1.15 1.06
KLA/ATP 1.39 1.48 1.64 1.42 1.07 .83 .95
Itpr3
KLA  ATP  ATP+KLA
NM_080553 inositol 1,4,5-triphosphate receptor 3 (Itpr3), mRNA [NM_080553] KLA .55 .51 .45 .41 .34 .34 .45
ATP 1.01 .92 1.02 .57 .46 .34 1.22
KLA/ATP .56 .48 .48 .29 .33 .27 .65
Kras
KLA  ATP  ATP+KLA
NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
LOC10004
8021
KLA  ATP  ATP+KLA
XM_001479354 ref|PREDICTED: Mus musculus similar to Guanine nucleotide-binding protein alpha-12 subunit (G alpha-12) (LOC100048021), mRNA [XM_001479354] KLA .29 .29 .23 .19 .25 .43 .47
ATP 1.03 1.08 .94 .88 .78 .52 .59
KLA/ATP .32 .29 .20 .22 .31 .47 .36
Lyn
KLA  ATP  ATP+KLA
NM_010747 Yamaguchi sarcoma viral (v-yes-1) oncogene homolog (Lyn), transcript variant 2, mRNA [NM_010747] KLA 2.48 2.80 3.76 3.81 5.30 4.57 2.46
ATP 1.06 1.18 .82 .97 .74 1.45 1.21
KLA/ATP 2.82 3.16 2.24 2.87 1.73 1.80 2.63
Map2k1
KLA  ATP  ATP+KLA
NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Mapk1
KLA  ATP  ATP+KLA
NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mm.22094
6
KLA  ATP  ATP+KLA
27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.27574
2
KLA  ATP  ATP+KLA
112983655 Unknown KLA 1.35 1.16 .94 .85 .45 .33 .31
ATP .90 .86 1.17 1.09 1.18 1.21 .38
KLA/ATP 1.12 1.22 1.19 .91 .90 .83 .33
Mm.33050
7
KLA  ATP  ATP+KLA
67906182 Unknown KLA .94 .98 .99 1.03 1.05 1.07 .98
ATP .95 1.02 .97 .98 .99 1.05 1.02
KLA/ATP 1.02 1.05 1.01 1.03 .99 .98 .97
Mm.44160
1
KLA  ATP  ATP+KLA
145966786 Unknown KLA 1.08 .94 1.01 .97 .79 .78 .71
ATP 1.09 .92 1.10 .75 .65 .92 .69
KLA/ATP 1.01 .92 1.16 .81 .69 .56 .63
Nos1
KLA  ATP  ATP+KLA
NM_008712 nitric oxide synthase 1, neuronal (Nos1), mRNA [NM_008712] KLA 1.01 1.01 1.02 .99 1.02 1.02 1.01
ATP 1.01 1.03 1.02 1.04 1.03 1.01 1.00
KLA/ATP 1.05 1.02 1.02 1.00 1.02 1.03 1.03
Nras
KLA  ATP  ATP+KLA
NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Pla2g4a
KLA  ATP  ATP+KLA
NM_008869 phospholipase A2, group IVA (cytosolic, calcium-dependent) (Pla2g4a), mRNA [NM_008869] KLA 3.93 4.49 4.86 6.40 6.44 3.10 1.68
ATP 1.13 1.36 1.27 1.30 1.02 5.37 1.47
KLA/ATP 3.64 4.45 4.76 7.11 2.96 4.08 2.60
Pla2g4b
KLA  ATP  ATP+KLA
NM_145378 phospholipase A2, group IVB (cytosolic) (Pla2g4b), mRNA [NM_145378] KLA 1.09 1.18 .95 1.01 .97 .97 .77
ATP 1.05 1.14 1.28 .94 .88 1.18 .70
KLA/ATP 1.23 1.43 1.21 1.02 1.15 1.16 .78
Pla2g4c
KLA  ATP  ATP+KLA
AK145339 1 cell embryo 1 cell cDNA, RIKEN full-length enriched library, clone:I0C0013F18 product:weakly similar to Cytosolic phospholipase A2 gamma [Homo sapiens], full insert sequence [AK145339] KLA 1.09 1.21 1.33 1.17 1.26 1.30 1.05
ATP .97 1.06 1.00 .98 .98 .98 1.05
KLA/ATP 1.19 1.16 1.18 1.13 1.04 1.02 1.06
Pla2g4c
KLA  ATP  ATP+KLA
NM_001004762 phospholipase A2, group IVC (cytosolic, calcium-independent) (Pla2g4c), mRNA [NM_001004762] KLA .93 1.00 .94 .93 .94 .94 .96
ATP .98 .96 1.13 .97 .99 .89 .96
KLA/ATP 1.01 1.01 1.07 1.01 .94 1.01 .92
Pla2g4e
KLA  ATP  ATP+KLA
AK049063 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230096D22 product:hypothetical Lysophospholipase catalytic domain containing protein, full insert sequence. [AK049063] KLA 1.03 1.09 1.01 1.01 1.06 .94 1.05
ATP 1.03 1.00 1.06 1.01 .96 1.05 1.05
KLA/ATP .98 1.00 1.01 .98 1.03 .95 1.01
Pla2g4e
KLA  ATP  ATP+KLA
NM_177845 phospholipase A2, group IVE (Pla2g4e), mRNA [NM_177845] KLA .97 .95 1.01 .97 1.02 1.03 1.05
ATP .98 .99 1.00 1.10 .98 1.00 1.02
KLA/ATP 1.05 .93 .96 1.03 1.08 1.05 .99
Pla2g4f
KLA  ATP  ATP+KLA
NM_001024145 phospholipase A2, group IVF (Pla2g4f), mRNA [NM_001024145] KLA 1.08 .99 1.04 1.02 1.04 .98 1.01
ATP .99 1.04 .99 1.03 1.12 1.01 1.25
KLA/ATP .97 1.04 1.10 1.06 1.04 1.03 1.03
Plcb1
KLA  ATP  ATP+KLA
AK129166 mRNA for mKIAA0581 protein [AK129166] KLA 1.02 .98 .91 .91 .92 .95 .89
ATP 1.03 1.02 1.02 1.01 .90 1.02 1.04
KLA/ATP .98 .97 .91 .93 .92 1.01 1.16
Plcb1
KLA  ATP  ATP+KLA
NM_019677 phospholipase C, beta 1 (Plcb1), mRNA [NM_019677] KLA .99 .94 .95 .97 .93 .92 .91
ATP 1.00 .96 .99 .95 .99 1.03 .98
KLA/ATP .93 .96 .94 .93 .87 1.00 1.06
Plcb2
KLA  ATP  ATP+KLA
NM_177568 phospholipase C, beta 2 (Plcb2), mRNA [NM_177568] KLA .70 .68 .64 .67 .65 .76 .88
ATP .95 .94 1.04 .94 .72 .57 1.19
KLA/ATP .69 .68 .72 .63 .65 .55 .70
Plcb3
KLA  ATP  ATP+KLA
NM_008874 phospholipase C, beta 3 (Plcb3), mRNA [NM_008874] KLA 1.72 1.78 1.82 1.65 1.67 1.44 1.21
ATP .97 1.04 .81 .87 .78 .88 .94
KLA/ATP 1.69 1.89 1.44 1.66 1.12 .73 .93
Plcb4
KLA  ATP  ATP+KLA
AK082509 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230058B11 product:unclassifiable, full insert sequence. [AK082509] KLA 1.06 1.03 .97 .98 1.02 1.01 .99
ATP .99 1.07 1.09 .95 .97 .97 1.02
KLA/ATP .98 1.00 1.03 .96 1.02 .91 .98
Plcb4
KLA  ATP  ATP+KLA
NM_013829 phospholipase C, beta 4 (Plcb4), mRNA [NM_013829] KLA .88 .94 .81 .82 .81 .86 1.01
ATP 1.00 1.01 .92 .93 .88 .85 .89
KLA/ATP .97 .94 .78 .80 .78 .86 .97
Ppp2ca
KLA  ATP  ATP+KLA
NM_019411 protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform (Ppp2ca), mRNA [NM_019411] KLA 1.17 1.13 1.18 1.20 1.54 1.45 1.34
ATP 1.09 1.20 1.07 1.33 1.56 2.04 1.43
KLA/ATP 1.14 1.17 1.15 1.49 1.59 2.37 2.02
Ppp2cb
KLA  ATP  ATP+KLA
NM_017374 protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform (Ppp2cb), mRNA [NM_017374] KLA 1.32 1.33 1.37 1.24 1.27 1.09 1.18
ATP .94 .93 .82 .91 1.22 2.01 1.08
KLA/ATP 1.24 1.14 .80 .97 1.13 1.54 1.18
Ppp2r1a
KLA  ATP  ATP+KLA
NM_016891 protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform (Ppp2r1a), mRNA [NM_016891] KLA 1.44 1.39 1.47 1.37 1.69 1.33 1.16
ATP 1.18 1.55 .85 1.67 1.38 .99 1.24
KLA/ATP 1.66 1.98 .97 2.33 1.41 1.65 1.38
Ppp2r1b
KLA  ATP  ATP+KLA
NM_001034085 protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 1, mRNA [NM_001034085] KLA 1.26 1.17 1.14 1.13 1.12 1.11 .99
ATP .90 .90 .96 .98 1.59 1.71 1.16
KLA/ATP 1.23 1.16 .99 1.00 1.54 1.34 1.24
Ppp2r1b
KLA  ATP  ATP+KLA
NM_028614 protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 2, mRNA [NM_028614] KLA 2.38 2.38 2.53 1.80 1.52 .95 1.16
ATP 1.17 1.29 1.04 1.09 1.16 1.19 1.00
KLA/ATP 2.59 2.78 1.82 2.31 1.34 1.03 .75
Prkca
KLA  ATP  ATP+KLA
NM_011101 protein kinase C, alpha (Prkca), mRNA [NM_011101] KLA 1.00 .96 .94 .95 .95 .89 .96
ATP 1.00 1.03 .91 .94 .82 .87 1.13
KLA/ATP 1.02 .95 .91 .86 .78 .84 .94
Prkcb1
KLA  ATP  ATP+KLA
NM_008855 protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] KLA .92 .95 .93 .78 .77 1.08 1.83
ATP 1.03 1.12 1.09 1.23 .90 2.08 .96
KLA/ATP .98 .99 .82 .89 .62 1.01 1.08
Prkcc
KLA  ATP  ATP+KLA
NM_011102 protein kinase C, gamma (Prkcc), mRNA [NM_011102] KLA 1.02 1.04 1.11 1.04 .96 1.02 1.05
ATP .98 .98 1.05 1.03 1.08 .96 .95
KLA/ATP 1.21 1.16 1.09 1.07 1.04 .98 .93
Prkg1
KLA  ATP  ATP+KLA
NM_011160 protein kinase, cGMP-dependent, type I (Prkg1), transcript variant 2, mRNA [NM_011160] KLA .97 .96 .97 1.08 1.11 .93 .94
ATP 1.07 .96 .94 .99 1.03 1.60 .90
KLA/ATP .95 1.07 1.00 1.04 1.00 1.04 .91
Prkg2
KLA  ATP  ATP+KLA
NM_008926 protein kinase, cGMP-dependent, type II (Prkg2), mRNA [NM_008926] KLA .97 1.03 1.03 1.02 1.15 .99 .98
ATP 1.02 1.08 .98 .98 1.00 1.00 1.02
KLA/ATP 1.01 1.02 1.03 .97 1.00 .93 1.02
Raf1
KLA  ATP  ATP+KLA
AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Ryr1
KLA  ATP  ATP+KLA
AK042482 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630095L05 product:RYANODINE RECEPTOR 1 (SKELETAL MUSCLE-TYPE RYANODINE RECEPTOR) (RYR1) (RYR-1) (SKELETAL MUSCLE CALCIUM RELEASE CHANNEL) homolog [Homo sapiens], full KLA 1.61 1.64 1.65 1.73 1.85 1.62 1.13
ATP 1.05 1.11 1.16 1.42 1.40 1.28 1.22
KLA/ATP 1.77 1.70 1.98 2.23 1.96 1.47 1.48
Ryr1
KLA  ATP  ATP+KLA
AK042482 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630095L05 product:RYANODINE RECEPTOR 1 (SKELETAL MUSCLE-TYPE RYANODINE RECEPTOR) (RYR1) (RYR-1) (SKELETAL MUSCLE CALCIUM RELEASE CHANNEL) homolog [Homo sapiens], full i KLA 1.52 1.58 1.63 1.69 1.73 1.53 1.25
ATP .99 .99 1.07 1.37 1.35 1.30 1.15
KLA/ATP 1.58 1.67 1.84 1.97 1.94 1.65 1.41
Ryr1
KLA  ATP  ATP+KLA
NM_009109 ryanodine receptor 1, skeletal muscle (Ryr1), mRNA [NM_009109] KLA .94 .93 .89 .91 .82 .86 .88
ATP 1.05 .98 .95 1.08 1.41 1.28 1.15
KLA/ATP .93 .95 .92 1.02 1.62 1.96 2.06